NFKB1 and hepatocellular carcinoma: Namodenoson (CF102) is an A3R agonist that induces dysregulation of the Wnt/β-catenin and NF-κB signaling pathways leading to apoptosis in HCC cells and is currently being used in phase III trials in advanced HCC [172, 173].